Medtronic has reported revenue gains across several of its medical device franchises, leading the company to ... aortic valve ...

Boston Scientific, Medtronic and J&J are moving quickly to secure their place in the fast-growing pulsed field ablation space ...

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

5.0%). The OPTION trial included 1,600 patients. In the trial, approximately 60% of device patients had their WATCHMAN FLX ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...